Evolving characteristics of toxoplasmosis in patients infected with human immunodeficiency virus-1: Clinical course and Toxoplasma gondii-specific immune responses

Clinical Microbiology and Infection

Volumn 13, Issue 5, 2007, Pages 510-515

  Hoffmann, C ^a,b,e   Ernst, M ^c   Meyer, P ^a   Wolf, E ^d   Rosenkranz, T ^e   Plettenberg, A ^b   Stoehr, A ^b   Horst, H A ^a   Marienfeld, K ^c   Lange, C ^c  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Institute for Interdisciplinary Medicine   (Germany)

^c RESEARCH CENTER BORSTEL   (Germany)

^d MUC Research GmbH and MVZ Karlsplatz   (Germany)

^e DEPARTMENT OF CARDIOLOGY   (Germany)

Author keywords

AIDS; ELISPOT; Encephalitis; HIV 1; Immune response; Toxoplasmosis

Indexed keywords

ANTIRETROVIRUS AGENT; GAMMA INTERFERON; PYRIMETHAMINE SULFADIAZINE;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; ENCEPHALITIS; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FREQUENCY ANALYSIS; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; KAPLAN MEIER METHOD; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; RISK ASSESSMENT; TOXOPLASMA GONDII; TOXOPLASMOSIS;

HUMAN IMMUNODEFICIENCY VIRUS 1; TOXOPLASMA GONDII;

EID: 34147186853     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2007.01683.x     Document Type: Article

References (23)

1. Abgrall S, Rabaud C, Costagliola D. Incidence and risk factors for toxoplasmic encephalitis in HIV-infected patients before and during the HAART era. Clin Infect Dis 2001; 33: 1747-1755.
2. Bonnet F, Lewden C, May T et al. Opportunistic infections as causes of death in HIV-infected patients in the HAART era in France. Scand J Infect Dis 2005; 37: 482-487.
3. Soriano V, Dona C, Rodriguez-Rosado R, Barreiro P, Gonzalez-Lahoz J. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2000; 14: 383-386.
4. Kirk O, Lundgren JD, Pedersen C, Nielsen H, Gerstoft J. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy? AIDS 1999; 13: 1647-1651.
5. Miro JM, Lopez JC, Podzamczer D et al. Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: Results of an open, randomized, multicenter clinical trial. Clin Infect Dis 2006; 43: 79-89.
6. Masur H, Kaplan JE, Holmes KK et al. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002. Recommendations of the US Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 2002; 137: 435-478.
7. Ghosn J, Paris L, Ajzenberg D et al. Atypical toxoplasmic manifestation after discontinuation of maintenance therapy in a HIV type 1-infected patient with immune recovery. Clin Infect Dis 2003; 37: 112-114.
8. Stout JE, Lai JC, Giner J, Hamilton CD. Reactivation of retinal toxoplasmosis despite evidence of immune response to highly active antiretroviral therapy. Clin Infect Dis 2002; 35: 37-39.
9. Tsambiras PE, Larkin JA, Houston SH. Toxoplasma encephalitis after initiation of HAART. AIDS Read 2001; 11: 608-610.
10. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993; 269: 729-730.
11. Antinori A, Larussa D, Cingolani A et al. Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy. Clin Infect Dis 2004; 39: 1681-1691.
12. Vidal JE, Hernandez AV, de Oliveira AC et al. Cerebral toxoplasmosis in HIV-positive patients in Brazil: Clinical features and predictors of treatment response in the HAART era. AIDS Patient Care STDS 2005; 19: 626-634.
13. Dannemann B, McCutchan JA, Israelski D et al. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. Ann Intern Med 1992; 116: 33-43.
14. Katlama C, De Wit S, O'Doherty E, Van Glabeke M, Clumeck N. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 1996; 22: 268-275.
15. Torre D, Casari S, Speranza F et al. Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group. Antimicrob Agents Chemother 1998; 42: 1346-1349.
16. Luft BJ, Hafner R, Korzun AH et al. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ ANRS 009 Study Team. N Engl J Med 1993; 329: 995-1000.
17. Connors M, Kovacs JA, Krevat S et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nature Med 1997; 3: 533-540.
18. Lange CG, Lederman MM, Medvik K et al. Nadir CD4+ T-lymphocyte count and numbers of circulating CD28/CD4+ T-lymphocytes predict functional responses to immunizations in chronic HIV-1 infection. AIDS 2003; 17: 2015-2023.
19. Lange CG, Valdez H, Medvik K, Asaad R, Lederman MM. CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection. Clin Immunol 2002; 102: 154-161.
20. Fournier S, Rabian C, Alberti C et al. Immune recovery under highly active antiretroviral therapy is associated with restoration of lymphocyte proliferation and interferon-γ production in the presence of Toxoplasma gondii antigens. J Infect Dis 2001; 183: 1586-1591.
21. Mussini C, Pezzotti P, Antinori A et al. Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: A randomized trial by the CIOP Study Group. Clin Infect Dis 2003; 36: 645-651.
22. Komanduri KV, Feinberg J, Hutchins RK et al. Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis. J Infect Dis 2001; 183: 1285-1289.
23. Johnson SC, Benson CA, Johnson DW, Weinberg A. Recurrences of cytomegalovirus retinitis in a human immunodeficiency virus-infected patient, despite potent antiretroviral therapy and apparent immune reconstitution. Clin Infect Dis 2001; 32: 815-819.